PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.
Diagnostic Imaging
DRUG: Bombesin (68Ga) labeled (BAY86-7548)|DRUG: Bombesin (68Ga) labeled (BAY86-7548)
Visual assessment of lesions, Day of study drug administration
Quantitative analysis of BAY86-7548 uptake into lesions (Standardized Uptake Values = SUVs), Day of study drug administration|ECG (significant abnormalities), At least 3 times until one day after treatment|Blood pressure, At least 3 times until one day after treatment|Serum protein, At least 3 times until one day after treatment|Serum creatinine, At least 3 times until one day after treatment|Serum GOT (Glutamat-Oxalacetat-Transaminase), At least 3 times until one day after treatment|Adverse events collection, Continuously for at least 5 days after treatment
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY86-7548 in patients with cancer.